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Letters e159with a maintenance therapy of intravenous immu-
noglobulins every 2 months.
The characteristic cutaneous manifestations in
SM, also known as generalized lichen myxedema-
tosus,1 is a widespread eruption of 2- to 3-mm, firm,
waxy papules, often in linear arrays, and the
sclerodermoid induration of the skin. These char-
acteristic skin findings were observed concomi-
tantly with other unusual clinical findings in this
patient. Nodular eruption3,4 and scalp involvement
leading to alopecia have been reported only
sporadically.3 Interestingly, the recently reported
cases, with a prominent nodular eruption, pre-
sented in absence of underlying paraproteinemia.3,4
Associated hematologic diseases in SM include
Waldenstr€om macroglobulinemia, Hodgkin lym-
phoma, and non-Hodgkin lymphoma, particularly
after chemotherapy with melphalan.1 To our
knowledge, immune thrombocytopenia has not
been reported previously in SM. Based on the
current classification,1 a final diagnosis of atypical
form was made (SM without monoclonal gammop-
athy). Long-term follow-up to further characterize
the natural course and prognosis in these patients is
required.
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To the Editor: Vemurafenib (PLX4032, Zelboraf,
Roche Registration Ltd, Welwyn Garden City, UK)
is a selective inhibitor of the oncogenic BRAF kinase
activity.1 The BRAFV600 mutation is the most com-
mon protein kinase mutation reported in melanoma
with a frequency of 40% to 50%.2,3 BRAF is a member
of the RAF kinase family, which acts in the ERK/MAP
kinase pathway, a signaling cascade regulating
cellular proliferation, differentiation, and survival.3
Vemurafenib treatment of patients with metastatic
melanoma carrying the BRAFV600E mutation results
in partial or complete tumor regression in the
majority of patients and increases overall survival
time.4,5
Common adverse events during vemurafenib
therapy include photosensitivity, fatigue, rash, and
arthralgia.4,5 Furthermore, approximately one third
of the patients develop epithelial tumors of the skin
such as warts, squamous cell carcinomas, and
keratoacanthomas.1,4,5
Hereby, we wish to report a case of lupus
erythematosuselike skin eruption after vemurafenib
therapy in a 70-year-old woman with stage IIIc
progressive metastatic melanoma (pT4bN3M0).
After excision of a 8-mm thick primary tumor on
the left upper aspect of her back and lymph node
dissection of the left axilla (7 metastatic of 19 lymph
nodes), the tumor reoccurred within 26 months.
Because the melanoma cells were found to have the
BRAFV600E mutation, vemurafenib therapy was
started at the regular daily dosage of 1920 mg. The
treatment was well tolerated for a total of 4 months
but then needed to be paused for 4 months because
of fatigue and nausea. Vemurafenib was reinitiated at
a total dose of 960 mg daily for 2 months and then
increased to 1920 mg twice daily for another 2
months. Because of gastrointestinal discomfort and
flareup of a rash the treatment was aborted. The rash
started with erythematous macules on the face and
subsequently over the next 2 to 4 weeks progressed
into demarcated, infiltrated, scaly plaques that were
symmetrically distributed over all sun-exposed body
areas, particularly the face, decollete, and upper
aspect of the back (Fig 1, A). Histopathology
revealed interface dermatitis with follicular plugging
and dermal mucin deposition consistent with a lupus
Fig 1. A, Sharply demarcated erythematous plaques in a
70-year-old woman developed in the context of vemur-
afenib melanoma therapy. B, Histology demonstrated
interface dermatitis with follicular plugging and dermal
mucin deposition consistent with lupus erythematosuse
like eruption. (B, Hematoxylin-eosin stain; original magni-
fication: 320.)
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e160 Letterserythematosuselike pattern (Fig 1, B). Indirect
immunofluorescence showed elevated antinuclear
antibody titers (1:320). Muscle creatine kinase was
normal, which excluded the differential diagnosis of
paraneoplastic dermatomyositis. There was no
increased photosensitivity after 24 hours of ultravi-
olet A/B exposition. Moreover, photopatch testing
also showed no sign of belated, increased photo-
sensitivity after 4 weeks. Topical treatment of these
lupus-like plaques was implemented with topical
mometasone furoate cream that lead to gradual
recovery within 4 weeks. In addition, the patient
was instructed as to the careful use of sun blockers.
Over the course of time the underlying diseaseprogressed, with radiotherapy and chemotherapy
needed.
The clinical and the histologic presentations of
our patient are consistent with a lupus erythemato-
suselike skin eruption that was most likely associ-
ated with the vemurafenib therapy. A paraneoplastic
reaction cannot totally be excluded but would be
unusual in the context of malignant melanoma.
Although the patient did not show increased photo-
sensitivity we speculate that both the already well-
known side effect of photosensitivity that can be an
initial symptom of lupus erythematosus and the
lupus erythematosuselike skin eruptions mark a
spec-trum of vemurafenib-induced drug reactions.
The pathomechanism behind this reaction pattern
needs further investigations.
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Localized insulin-dependent amyloidosis with
scar-tissue formation
To the Editor: The incidence and prevalence of
diabetes mellitus has increased dramatically in the
last few years as a result of increasing prevalence of
